Fluzoparide combined with apatinib mesylate in the treatment of platinum resistant recurrent ovarian cancer: A single arm, single center, prospective clinical study

被引：0
|
作者：
Sun, L. X. [1 ]
Zhao, H. W. [1 ]
机构：
[1] Shanxi Canc Hosp, Dept Med, Taiyuan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
823TiP
引用
收藏
页码：S772 / S772
页数：1
相关论文
共 50 条
  • [11] Apatinib combined with irinotecan in the treatment of small cell lung cancer: A phase II, single-arm, prospective study
    Zhao, Y.
    Guo, L.
    Pu, H.
    Bai, S.
    Yang, M.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1043 - S1043
  • [12] Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study
    Ren, Yulan
    Wang, Tingting
    Cheng, Xi
    Ke, Guihao
    Huang, Yan
    Yang, Huijuan
    Huang, Xiao
    Tian, Wenjuan
    Wang, Huaying
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [13] Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study
    Zhang, Jindi
    Li, Anyang
    Jiang, Qi
    Zheng, Feiyun
    Zhu, Haiyan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 3913 - 3918
  • [14] Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study
    Huang, Qi
    Chu, Chaonan
    Tang, Jie
    Dai, Zhijie
    JOURNAL OF CANCER, 2020, 11 (18): : 5353 - 5358
  • [15] Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study
    Qu, Yanli
    Munire, Abulimiti
    Zhou, Ning
    Saifuding, Keyoumu
    Bulibu, Jilisihan
    Wang, Wei
    Tang, Xushan
    Li, Na
    Li, Junjie
    Wang, Peihong
    Tang, Yong
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (01) : 1 - 11
  • [16] Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: A single-arm, open-label, phase 2 study
    Lan, Chunyan
    Wang, Yin
    Xiong, Ying
    Li, Judong
    Li, Yanfang
    Zhang, Yanna
    Zheng, Min
    Feng, Yanling
    Huang, Huiqiang
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [17] Efficacy and safety of apatinib in the treatment of advanced platinum-resistant recurrent epithelial ovarian cancer: A retrospective study.
    Pan, Zhongmian
    Luo, Zhongbin
    He, Hongying
    Chen, Yujie
    Zhao, Bingbing
    Yang, Zhijun
    Li, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17594 - E17594
  • [18] The role of low-dose decitabine combined with chemotherapy in the treatment of recurrent and refractory gastric cancer: a single-center, single-arm clinical study
    Zhang, Yan
    Yuan, Qinggong
    Cao, Gang
    Li, Junhui
    Yang, Wenbin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (04): : 4273 - +
  • [19] Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
    Wu, Yawen
    Zhang, Xiaoyan
    Li, Lian
    Yang, Wen
    Yan, Zhifeng
    Gu, Chenglei
    Zhang, Zhe
    Zhou, Jiahuan
    Liu, Lulu
    Ye, Mingxia
    Meng, Yuanguang
    ONCOTARGETS AND THERAPY, 2022, 15 : 973 - 979
  • [20] Anlotinib plus letrozole in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study.
    Wang, Xipeng
    Li, Jiarui
    Zhang, Ping
    Fang, Xuhong
    Wang, Yizhi
    Sun, Huizhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17545 - E17545
12345